HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab

Although current breast cancer treatment guidelines limit the use of HER2 blocking agents to tumors with HER2 gene amplification, recent retrospective analyses suggest that a wider group of patients may benefit from this therapy. Utilizing breast cancer cell lines, mouse xenograft models and matched...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ithimakin, Suthinee, Day, Kathleen C., Malik, Fayaz, Zen, Qin, Dawsey, Scott J., Bersano-Begey, Tom F., Quraishi, Ahmed A., Ignatoski, Kathleen Woods, Daignault, Stephanie, Davis, April, Hall, Christopher L., Palanisamy, Nallasivam, Heath, Amber N., Tawakkol, Nader, Luther, Tahra K., Clouthier, Shawn G., Chadwick, Whitney A., Day, Mark L., Kleer, Celina G., Thomas, Dafydd G., Hayes, Daniel F., Korkaya, Hasan, Wicha, Max S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600586/
https://ncbi.nlm.nih.gov/pubmed/23442322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3349
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados